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Abstract [word count 250] 
Objectives Determinants of atrial fibrillation (AF) patterns and of progression of earlier forms to 
permanent AF, and their relation with outcome are still poorly understood. 
Methods We examined AF patterns (paroxysmal, persistent, permanent), rate and predictors of 
AF progression, and outcomes in the PREFER (PREvention oF thromboembolic events-
European Registry) in AF. The primary analysis was performed in the PREFER in AF 
prolongation data set (N=3223 AF patients with complete 1-year follow-up, mean age 72±9 
years, 40% women). Sensitivity analyses were performed using the PREFER in AF study 
(N=6390 patients). 
Results AF progressed to more persistent types in 506 patients (17%). Permanent AF was 
associated with development of heart failure at one year (odds ratio (OR) 1.80, 95% confidence 
interval (CI) 1.06-3.07, P=0.03) compared to paroxysmal AF (PAF), which was confirmed in the 
entire cohort. In multivariable-adjusted models, sinus rhythm at baseline, AF duration, 
cardioversion, hyperthyroidism, valvular heart disease, diabetes mellitus, and heart failure were 
predictors of AF progression (area under the receiver operating characteristic curve 0.60, 95% 
CI 0.57-0.63). Results were similar when we restricted analyses to patients with AF duration <1 
year. AF progression showed an association with coronary events over one year (OR 2.27, 95% 
CI 1.22-4.19, P=0.0074).  
Conclusions Permanent AF at baseline was associated with incident heart failure. A 
substantial proportion of well-managed AF patients showed AF progression over one year. AF 
progression itself was not strongly related to outcome and may indicate the need to refine the 
current classification of AF types to enhance clinical utility.  
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What is already known about this subject? 
Atrial fibrillation appears to be a progressive disease. Non-paroxysmal atrial fibrillation has been 
associated with adverse outcomes. Clinical predictors of atrial fibrillation may exist.  
 
What does this study add? 
This study shows that almost half of the patients with atrial fibrillation duration less than one 
year were in permanent atrial fibrillation. Atrial fibrillation revealed a significant progression rate 
over one year (17%). Permanent atrial fibrillation was associated with increased risk of 
developing heart failure. Determinants of atrial fibrillation progression comprised atrial fibrillation 
duration, diabetes mellitus, heart failure, hyperthyroidism, sinus rhythm at baseline, 
cardioversion, and valvular heart disease.  
 
How might this impact on clinical practice? 
Atrial fibrillation is a progressive disease during a comparatively short one-year time frame 
which needs to be considered when treating patients with the rhythm disorder. Modifiable 
clinical predictors of atrial fibrillation progression exist and may represent targets for intervention 
to reduce progression rate. New, prognostically relevant patterns of atrial fibrillation may need to 
be defined. 
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INTRODUCTION 
Atrial fibrillation (AF) burden is increasing worldwide,[1] and constitutes a progressive disease in 
most cases.[2, 3] The arrhythmia carries a high risk of complications such as thromboembolic 
events, heart failure, and coronary events. Anticoagulation therapy used to reduce stroke risk 
increases bleeding disposition. Chronic AF patterns (persistent, long-standing persistent, and 
permanent AF) appear to be associated with an increased thromboembolic risk compared to 
PAF as shown by a recent meta-analysis.[4] Early AF recurrence and persistent AF have been 
associated with a higher mortality and an increased risk of stroke and heart failure in the 
community compared to paroxysmal types or lack of recurrence after an initial episode.[5] In 
patients, disease progression seems to be accompanied by a higher risk of adverse events.[6, 
7] Furthermore, mortality is increased with longer episodes of AF, which may be confounded by 
clinical characteristics in patients with non-PAF.[8, 9] Current guidelines categorize AF into 
paroxysmal, persistent, long-standing persistent and permanent based on duration and 
termination of episodes. In addition, new onset disease represents a specific category. The 
relevance of AF patterns in clinical practice has not been fully defined. Further, the progression 
rate of AF and its clinical correlates remain unclear. A prior publication addressed predictors for 
AF progression in patients with PAF.[10] Hypertension, age, transient ischemic attack (TIA) or 
stroke, chronic obstructive pulmonary disease and heart failure (HATCH score) were identified 
as predictors of AF progression in PAF. The score replicated only modestly in independent 
cohorts.[8, 11] Therefore, a systematic examination of indicators of AF progression across the 
spectrum of AF types is required. Further data are needed relating AF type to cardiovascular 
outcomes in clinical practice. Therefore, we used the PREFER in AF (PREvention oF 
thromboembolic events - European Registry in Atrial Fibrillation) registries to examine the 
clinical impact of AF type and progression on prognosis and to elucidate predictors of disease 
progression. 
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METHODS  
Study sample 
We analyzed two similarly structured contemporary European registries on epidemiology, 
management and outcome in all-comers with AF, the PREFER in AF and its Prolongation study. 
The study design and primary results of PREFER in AF have been published previously.[12]  
In brief, the PREFER in AF registry enrolled 7,243 AF patients at least 18 years across seven 
European countries from 2012-2014. At one year, information was collected by questionnaire 
with last follow-up in January 2014. Enrolment took place at 461 sites, which were 
predominantly cardiology practices and hospitals. N=6412 patients completed follow-up. From 
N=22 patients AF type at baseline was missing, leaving N=6390 patients for analysis. 
The PREFER in AF Prolongation registry is an extension of the PREFER in AF registry that 
enrolled N=3597 patients from June 2014 to May 2015 and including sites that had already 
participated in the PREFER in AF registry (N=412). They had to be on non-vitamin K antagonist 
oral anticoagulant treatment at enrolment. As data on AF type were available at baseline and 
follow-up in the PREFER in AF Prolongation registry, the primary analysis was performed in this 
cohort. N=3223 had complete 1-year follow-up information, last follow-up June 2016. A total of 
3223 patients had complete 1-year follow-up data at the last follow-up (June 2016). As data on 
AF type at baseline were missing in 13 patients, the analysis was performed in 3210 patients. 
The PREFER in AF data set was used for validation using available information on baseline AF 
type. 
Clinical variables 
All patients had AF documented by ECG and diagnosed by a physician. AF pattern information 
was in accordance with the ESC/EACTS guidelines.[13] As there was a small number of 
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patients with longstanding persistent AF (N=132 in PREFER in AF Prolongation; N=516 in 
PREFER in AF) this category was combined with permanent AF for analysis. A total of 55 
patients in the PREFER in AF Prolongation and 103 in the PREFER in AF study were classified 
as permanent AF but showed sinus rhythm on study ECG, and were categorized as persistent 
AF. Sensitivity analyses confirmed that the results did not change markedly after reclassification 
of these individuals. We performed additional analyses in patients with AF onset <12 months. 
Outcomes 
AF type at 1-year follow-up was the primary outcome. We assumed a disease progression if 
patients with PAF at baseline were classified as persistent or permanent AF at follow-up and if 
patients with persistent AF on enrolment were diagnosed with permanent AF after one year. 
Prevalent cardiovascular disease incorporated coronary heart disease, peripheral arterial 
disease and myocardial infarction. 
We evaluated the following disease outcomes: ischemic stroke/ (TIA) /arterial embolism, 
coronary events (acute coronary syndrome/coronary revascularization), heart failure (physician 
diagnosis and/or reduced left ventricular ejection fraction), and major bleeding (cerebrovascular 
bleeding, major gastrointestinal or other bleeding events requiring hospitalization or blood 
transfusion). AF type and outcomes were assessed at follow-up. 
Local Ethics Committees in Austria, Germany, Switzerland, Italy, Spain, France and UK 
provided their approval as required by national regulations. All participants provided written, 
informed consent. The authors had full access to the data and take responsibility for its integrity. 
All authors have read and agreed to the manuscript as written.  
Statistical analyses  
Data were analyzed separately for the PREFER in AF Prolongation and PREFER in AF studies. 
Complete case analysis was performed, after we had formally tested whether data were missing 
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completely at random. Data are presented as mean±standard deviation (SD) for continuous 
variables, or median (25th/75th percentile) for skewed variables, and as number (percentage) 
for discrete variables. We compared the overall proportion of individuals with progression to 
patients stable or less advanced disease state by McNemar's test. We performed logistic 
regression analyses to relate baseline variables to progression of AF over one year in PREFER 
in AF Prolongation. A logistic stepwise variable selection model as implemented in SAS was 
applied to identify the strongest predictors of AF progression. All baseline variables were 
permitted to enter the model. The C-statistic as implemented in SAS proc logistic using ROC 
statement (the area under the Receiver Operating Characteristic (ROC) curve (AUC)) was 
calculated to understand the discriminatory ability of the combination of all selected clinical 
baseline variables to predict AF progression. We compared the discriminatory ability of our 
model to the previously reported HATCH score using its variables hypertension, age, transient 
ischemic attack (TIA) or stroke, chronic obstructive pulmonary disease and heart failure.[6]  
AF progression at follow-up was related to outcomes using logistic regression analyses. 
Furthermore, unadjusted and multivariable-adjusted regression analyses were performed to 
relate baseline AF type to one-year outcomes, adjusted for age, sex, and country. Comparison 
of persistent and permanent AF to PAF was used as the reference. Patients with prevalent heart 
failure at baseline were excluded from analyses on the incident condition.  
We performed sensitivity analyses for regression analyses using PAF vs. non-PAF types 
combined. For these analyses, sinus rhythm was not permitted to enter the stepwise model. 
Results are based on PREFER in AF Prolongation data if not stated otherwise.  
SAS software version 9.4 (Cary, North Carolina, USA) was used for statistical computations. A 
two-tailed significance threshold of 0.05 indicated statistical significance. 
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RESULTS 
Baseline patient characteristics 
In Table 1 baseline characteristics of the PREFER in AF Prolongation patients are detailed by 
type of AF. Patients with permanent AF were older, had a longer AF duration, and accumulated 
cardiovascular risk factors such as hypertension, diabetes, dyslipidemia, chronic pulmonary 
disease, and valvular heart disease. Individuals with permanent AF also had the highest 
proportion of a history of thromboembolic events and major bleedings. Almost half of the 
patients with persistent AF had a cardioversion in the year prior to enrolment (p<0.05 compared 
to other AF patterns). Clinical characteristics were similar in the PREFER in AF registry 
(Supplementary Table 1). The distribution of AF type at baseline for the total PREFER in AF 
Prolongation study and for the subgroup of patients with AF duration <1 year, N=1738 are 
shown in Supplementary Figure 1. Among patients with AF duration <1 year, approximately 
half (N=555, 52%) had non-paroxysmal types of AF at baseline. 
Table 1. Baseline characteristics of PREFER in AF Prolongation patients by atrial fibrillation 
type 
 
Variables 
Paroxysmal 
N=1337 
Persistent 
N=814 
Permanent 
N=1059 
P Value 
Age, years (SD) 70.9±9.4 70.4±9.5 75.4±8.5 <0.001 
Women, N (%) 595 (44.5) 291 (35.7) 399 (37.7) <0.001 
Body mass index, kg/m² (SD) 27.7±4.9 28.2±5.1 28.5±4.8 <0.001 
Systolic blood pressure, mm Hg 
(SD) 
135±16 134±17 133±16 0.09 
Heart rate, bpm (SD) 71.8±18.3 76.6±19.2 76.4±14.8 <0.001 
Atrial fibrillation duration, years  1.2 (0.2, 4.0) 0.8 (0.2, 2.8) 2.7(1.0, 7.3) <0.001 
Arterial hypertension, N (%) 1011 (75.8) 601 (74.3) 845 (79.8) 0.01 
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Table 1. Baseline characteristics of PREFER in AF Prolongation patients by atrial fibrillation 
type 
 
Variables 
Paroxysmal 
N=1337 
Persistent 
N=814 
Permanent 
N=1059 
P Value 
Ever smoking, N (%) 461 (35.6) 288 (36.1) 363 (35.0) 0.9 
Alcohol abuse, N (%) 40 (3.0) 36 (4.5) 42 (4.0) 0.2 
Diabetes mellitus, N (%) 305 (22.9) 182 (22.4) 256 (24.2) 0.63 
Dyslipidaemia, N (%) 546 (41.6) 303 (37.9) 458 (43.9) 0.04 
Prevalent cardiovascular 
disease, N (%) 
286 (21.5) 149 (18.8) 257 (24.5) 0.01 
Prevalent heart failure, N (%) 278 (20.8) 227 (28.0) 292 (27.6) <0.001 
History of ischemic 
stroke/TIA/other ischemic-
thromboembolic event, N (%) 
226 (16.9) 103 (12.7) 198 (18.7) <0.001 
Chronic renal insufficiency, N (%) 229 (17.4) 150 (18.6) 251 (23.9) <0.001 
Chronic hepatic disease, N (%) 10 (0.8) 7 (0.9) 14 (1.3) 0.34 
Hyperthyroidism, N (%) 60 (4.5) 37 (4.6) 29 (2.8) 0.05 
Chronic obstructive pulmonary 
disease, N (%) 
105 (7.9) 62 (7.6) 111 (10.5) 0.03 
Major 
gastrointestinal/cerebrovascular/
other bleeding events, N (%) 
39 (2.9) 17 (2.1) 65 (6.1) <0.001 
Sinus rhythm, N (%) 968 (72.8) 362 (44.6) 0 (0.0) <0.001 
Heart valve dysfunction, N (%) 425 (32.0) 314 (38.8) 450 (42.9) <0.001 
Antiarrhythmic drugs, N (%) 856 (64.0) 498 (61.2) 426 (40.2) <0.001 
Cardioversion in the last 12 
months, N (%) 
350 (26.2) 388 (47.7) 122 (11.5) <0.001 
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Mean ± standard deviation (SD) or median (25th/75th percentile) for skewed data are provided 
for continuous variables, number and percent for discrete values. Prevalent cardiovascular 
disease indicated coronary heart disease, peripheral arterial disease and myocardial infarction. 
TIA stands for transient ischemic attack. 
AF progression at one-year follow-up was observed in N=506 (16.5%) of patients. Figure 1A 
shows that N=242 (19%) of individuals with PAF and N=264 (34.4%) with persistent AF had a 
progression. In patients with a new diagnosis of AF <1 year, the progression rate was N=217 
(20.4%) (Figure 1B). Whereas the majority of PAF patients remained in PAF, similar 
proportions of patients with persistent AF remained in the same category or showed progression 
over one year. Among patients who transitioned into permanent atrial fibrillation after one year, 
12.8% were on antiarrhythmic drug therapy, 15.4% had undergone cardioversion and 8.3% had 
had an ablation therapy.  
A regression of AF type was observed in persistent AF patients (N=115, 32%). 
Type of AF and outcomes 
In unadjusted logistic regression analyses we identified statistically significant associations of 
AF type with incident heart failure (OR 1.80, 95% CI 1.06-3.07; P=0.029), which lost statistical 
significance after multivariable adjustment (Table 2). In the larger PREFER in AF registry there 
was an association of similar magnitude for both, permanent and persistent AF versus PAF 
(Supplementary Table 2). Further, permanent AF compared to PAF was inversely related to 
coronary events, but no signal was seen in PREFER in AF. 
 
Table 2. Logistic regression analyses for atrial fibrillation type in relation to one-year 
outcomes in PREFER in AF Prolongation 
 
Outcome 
 
OR           95% CI P value 
Stroke/TIA/arterial  
embolism, N=49 
Persistent vs. PAF 1.46 0.72 2.94 0.29 
 1.12 0.54 2.32 0.77 
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Table 2. Logistic regression analyses for atrial fibrillation type in relation to one-year 
outcomes in PREFER in AF Prolongation 
 
Outcome 
 
OR           95% CI P value 
Permanent vs. PAF 1.28 0.65 2.51 0.48 
 1.06 0.52 2.15 0.87 
Heart failure*, N=75 
Persistent vs. PAF 1.30 0.70 2.41 0.40 
 1.48 0.77 2.86 0.24 
Permanent vs. PAF 1.80 1.06 3.07 0.03 
 1.52 0.86 2.71 0.15 
 
Coronary event, N=50  
Persistent vs. PAF 1.05 0.56 1.98 0.87 
 0.89 0.45 1.75 0.72 
Permanent vs. PAF 0.45 0.21 0.98 0.04 
 0.41 0.18 0.90 0.03 
Major bleeding, N=62 
Persistent vs. PAF 1.39 0.71 2.72 0.34 
 1.26 0.63 2.53 0.51 
Permanent vs. PAF 1.83 1.01 3.31 0.05 
 1.52 0.81 2.83 0.19 
*Patients with heart failure at baseline were excluded from analyses (N=797). 
The upper row model is unadjusted. The lower row model is age-, sex- and country-adjusted. 
 
Predictors of AF progression 
Table 3 shows results of the regression analyses relating clinical variables to AF progression. 
AF duration (OR 0.95, 95% CI 0.93-0.98; P<0.001) and sinus rhythm at baseline (OR 0.63, 95% 
CI 0.51-0.77; P<0.0001) were inversely related to AF progression in unadjusted analyses. 
Prevalent heart failure (OR 1.38, 95% CI 1.12-1.71; P<0.001), hyperthyroidism (OR 1.68, 95% 
CI 1.09-2.59; P=0.02) valvular heart disease (OR 1.37, 95% CI 1.13-1.66; P<0.001), and 
cardioversion (OR 1.32, 95% CI 1.08-1.63; P=0.01) showed a positive association with 
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progression. These variables and diabetes mellitus were selected as the strongest predictors of 
AF progression by logistic stepwise selection using all variables presented in Table 3 (Figure 
2). The C-statistic of the selected variables combined was 0.64 and significantly differed from 
the results when using the HATCH score, C-statistic 0.52, P=0.0001. Results from stepwise 
selection models in patients with AF progression <1 year are shown in Supplementary Figure 
2. The selected variables were comparable with the total cohort except for hyperthyroidism, 
heart valve dysfunction and diabetes that did not enter the model. In addition, prevalent 
cardiovascular disease with a positive association and antiarrhythmic drug use with an inverse 
association were selected. Results of regression analyses for paroxysmal versus non-
paroxysmal AF are shown in Supplementary Table 3. The stepwise regression model 
excluding sinus rhythm as a predictor variable is provided in Supplementary Table 4. 
Table 3. Logistic regression analysis for predictors of progression of atrial fibrillation over one 
year in PREFER in AF Prolongation 
Variable Odds ratio 95% Confidence interval P value 
Age 1.01 1.00 1.02 0.30 
 1.00 0.99 1.02 0.35 
Body mass index 1.00 0.98 1.02 0.82 
 1.00 0.98 1.02 0.70 
Systolic blood pressure 1.00 0.99 1.03 0.41 
 1.00 0.99 1.01 0.76 
Heart rate 1.01 1.00 1.02 <0.001 
 1.01 1.00 1.02 0.02 
Atrial fibrillation duration 0.95 0.93 0.98 <0.001 
 0.95 0.93 0.98 <0.001 
Arterial hypertension 0.92 0.73 1.15 0.45 
 0.88 0.70 1.11 0.30 
Ever smoking 1.00 0.81 1.22 0.96 
 0.99 0.80 1.23 0.91 
Alcohol abuse 0.66 0.37 1.18 0.16 
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Table 3. Logistic regression analysis for predictors of progression of atrial fibrillation over one 
year in PREFER in AF Prolongation 
Variable Odds ratio 95% Confidence interval P value 
 0.68 0.38 1.24 0.21 
Diabetes mellitus 1.22 0.98 1.52 0.07 
 1.23 0.98 1.53 0.07 
Dyslipidaemia 0.95 0.78 1.15 0.58 
 0.94 0.77 1.15 0.57 
Prevalent cardiovascular disease 1.11 0.88 1.39 0.39 
 1.12 0.88 1.42 0.35 
Prevalent heart failure 1.38 1.12 1.71 <0.001 
 1.37 1.10 1.71 <0.001 
Stroke/ TIA/ thromboembolism 1.05 0.81 1.36 0.71 
 1.01 0.78 1.32 0.92 
Chronic renal insufficiency 0.94 0.74 1.20 0.64 
 0.96 0.75 1.23 0.74 
Chronic hepatic disease 2.14 0.93 4.92 0.07 
 2.00 0.87 4.64 0.10 
Hyperthyroidism 1.68 1.09 2.59 0.02 
 1.76 1.14 2.72 0.01 
Chronic obstructive pulmonary 
disease 
1.01 0.72 1.43 0.94 
 0.95 0.67 1.34 0.75 
Major bleeding 0.68 0.38 1.23 0.20 
 0.63 0.35 1.14 0.12 
Heart valve dysfunction  1.37 1.13 1.67 <0.001 
 1.38 1.12 1.69 <0.001 
Sinus rhythm 0.63 0.51 0.77 <0.001 
 0.65 0.53 0.80 <0.001 
Antiarrhythmic drugs 0.99 0.82 1.20 0.91 
 1.03 0.85 1.26 0.75 
Cardioversion in the last 12 months 1.32 1.08 1.63 0.01 
 1.36 1.10 1.69 <0.001 
ORs are per one unit increase for continuous variables or for the condition present for 
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Table 3. Logistic regression analysis for predictors of progression of atrial fibrillation over one 
year in PREFER in AF Prolongation 
Variable Odds ratio 95% Confidence interval P value 
dichotomous variables. The upper row model is unadjusted. The lower row model is age-, sex-  
and country-adjusted. Data are based on N=3063 individuals with complete follow-up 
information. 
In Table 4 AF progression in relation to outcomes is shown. We observed an association of AF 
progression with coronary events (OR 2.27, 95% CI 1.22-4.19; P=0.01). 
Table 4. Univariate logistic regressions for atrial fibrillation progression in relation to one-
year outcomes in PREFER in AF Prolongation 
 
Outcome  
 
Odds ratio 
 
95% Confidence interval 
 
P value 
Stroke/TIA/arterial embolism, N=47 0.47 0.17 1.30 0.14 
Heart failure, N=70* 1.26 0.68 2.33 0.45 
Coronary event, N=49 2.27 1.22 4.19 0.01 
Major bleeding, N=59 0.57 0.24 1.33 0.18 
Hazard ratios and 95% CIs are provided. Data are based on N=3063 individuals with 
complete follow-up information. *Patients with heart failure at baseline were excluded from 
analyses (N=797). 
 
The sensitivity analyses for PAF versus non-PAF types showed similar results with the same 
directions of associations (Supplementary Table 5). The strength of association was weaker 
due to the small number of patients with PAF progression to more permanent types (N=242). 
AF duration in PAF was not associated with progression.   
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DISCUSSION 
Main findings 
In our AF cohort the majority of patients was in non-PAF. Even in individuals with an AF 
duration of <1 year almost 50% had persistent or permanent AF. The progression rate over one 
year was substantial. Permanent AF was associated with new development of heart failure, and 
AF was associated with coronary events. We identified clinical parameters that were associated 
with AF progression, but there is a clear need to identify better markers for AF progression. 
 
AF type and progression 
It is recognized that clinical characteristics of patients differ across AF type. Patients with 
permanent AF are older and show more, possibly AF-related, complications such as a history of 
thromboembolic events, heart failure or bleeding besides the longer AF duration. 
The majority of patients presenting in clinical practice are in non-PAF. We further saw that when 
first diagnosed, AF did not necessarily evolve from PAF. Among patients with a diagnosis of AF 
within 12 months, 47% were classified as non-PAF. In both groups, patients with a long-
standing diagnosis of AF and with AF duration <1 year, we observed a substantial progression. 
In the latter, one fifth of the patients developed chronic forms of AF in one year. A higher 
proportion of individuals in persistent AF progressed compared to PAF patients.  
We also observed a regression in AF type from persistent to PAF. Some patients may be 
defined as persistent while presenting with similar AF burden and duration as others who are 
defined as paroxysmal.[11] AF regression is probably a biological fact and has been reported 
earlier.[12] The relatively large proportion of patients that was classified as persistent AF at 
baseline and PAF after one year, however, may be due to cardioversion therapy prior to 
baseline that automatically classifies patients into persistent AF whereas later on, paroxysms of 
AF that terminate spontaneously may occur. 
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Predictors AF progression 
In multivariable models, we identified several clinical predictors of AF progression. Among 
these, heart failure has been related to AF incidence and progression.[6, 13] It is 
pathophysiologically plausible that structural and functional cardiac changes contribute to the 
initiation and perpetuation of AF. Heart failure has been reported as an indicator of AF 
progression in the Euro Heart Survey.[14] In this cohort the HATCH score was developed in 
PAF patients.[15] In the present study, we extend this finding towards a cohort across the 
spectrum of PAF and persistent AF and identified the following additional predictors: the 
duration of AF, diabetes, hyperthyroidism, and valvular disease. In our cohort, the HATCH score 
replicated poorly as has been reported in other studies.[2, 8] These findings underlines that with 
current variables it is difficult to predict AF progression. 
Of note, the time since AF diagnosis was inversely related to progression, indicating a faster 
dynamic in change early after the first diagnosis of AF, with a possible stabilization of disease 
phenotype later during the disease course. A higher progression rate early during PAF has been 
reported in the Canadian Registry of Atrial Fibrillation, but with a much lower percentage, i.e. 
8.6%.[14] The absolute rate of AF progression will depend on patient characteristics as well as 
on the intensity of rhythm control treatment.  
Diabetes and hyperthyroidism as well as valvular heart disease constitute treatable conditions. It 
seems sensible to consider good management of these conditions to slow AF progression, 
especially in patients undergoing rhythm control therapy. Hyperthyroidism is well known in 
association with AF incidence and recurrence.[15, 16] We can now demonstrate that it is also 
correlated with progression of AF type. There are two likely explanations: Mechanisms triggered 
by hormonal imbalance that lead to AF onset also produce the substrate for AF recurrence and 
perpetuation of disease.[17] Furthermore, hyperthyroidism limits anti-arrhythmic drug therapy, in 
particular with amiodarone, and may result in a higher AF progression rate. We could not 
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confirm hypertension, TIA or stroke nor chronic obstructive pulmonary disease as strong 
predictors of AF progression as reported in the HATCH score. The lack of validation may be due 
to underlying differences in the studies. In particular, our cohort comprised a broader range of 
AF types and may thus not be comparable directly.  
A possible correlation of progression of PAF with mortality has been reported.[3, 6] We could 
demonstrate an association with coronary events, but not with other AF-related events, which 
may be limited by the comparatively small number of outcomes during the one year 
observational period.  
 
AF type and outcome 
Over the one year follow-up period we observed an association for AF type with coronary 
events and a borderline association with heart failure incidence. For coronary events the 
direction of association was inverse and only present for permanent AF compared to PAF. No 
significant results for persistent versus PAF were demonstrated. In addition, there was no signal 
of an association in PREFER in AF with more than three times the number of outcomes. 
Therefore we assume that the results are spurious findings. 
Similarly as discussed for AF progression, heart failure and AF are two closely interrelated 
diseases that share common pathophysiological pathways and perpetuate each other.[18] 
Hence, permanent AF may reflect a more advanced AF disease state that could be associated 
with manifestation of heart failure. The presence of AF could additionally worsen ventricular 
function as has been shown for patients with tachycardiomyopathy.[19, 20] Our associations 
seen over one year were consistent in both registries; however, validation in independent 
cohorts is required. Ongoing clinical trials evaluating heart failure as an outcome will examine 
the impact of maintaining sinus rhythm on ventricular function.[21] 
We could not demonstrate an impact of AF pattern on thromboembolic events, but the low 
overall event rate observed in the PREFER registries precludes firm conclusions. A trend 
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towards higher risk of thromboembolic events in chronic AF compared to PAF was confirmed by 
a meta-analysis comprising almost 100,000 patients.[4] There was substantial heterogeneity 
among studies and in the individual studies, the association was not uniform. For example, in 
large, contemporary trials such as the ROCKET-AF study patients with persistent AF had higher 
thromboembolic event rates,[22] whereas in the Euro Heart Survey there was no clear 
difference in event rates between PAF and persistent AF.[23] In the present study, the majority 
of patients received oral anticoagulation therapy and showed a low thromboembolic event rate 
across AF subtypes accordingly. Beyond the comparison of PAF versus more persistent types, 
we further had the opportunity to examine the subgroups of permanent and persistent AF in 
relation to outcomes. However, we could not demonstrate a gradient in associations for 
thromboembolic events either. In line with the recent meta-analysis [4] we could not show an 
association of AF type with bleeding risk. 
 
Limitations 
The number of events over the one-year follow-up period was relatively small. However, we had 
good power to detect moderate to strong associations.[6] A high follow-up rate of 95% should 
largely eliminate bias due to incomplete information on outcomes. Inherent to the currently used 
AF patterns, which do not reflect the true AF burden, we might have seen different associations 
if the actual frequency and duration of AF episodes had been known. Interactions in the 
relations of the different predictors of AF progression are pathophysiologically plausible. A 
formal statistical testing was not performed due to the comparatively small number of cases. 
Further, it needs to be considered that the current definition of AF subtypes incorporates both, 
pathophysiological and physician’s subjective assessment where psychosocial factors and 
management strategies may play a role. In older and sicker patients including those with heart 
failure AF will more likely be accepted as permanent by the treating physician and fewer 
attempts at restoration of sinus rhythm will be made. The AF subtype definition therefore not 
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necessarily reflects the pathophysiology of the disease course but many factors in the patient 
physician interaction. Therefore, the classification is not objective and may be subject to bias.  
 
The strength of our study is that we present data in a large, contemporary cohort that provides 
insights into AF distribution and its progression and a broad spectrum of clinically relevant 
outcomes using the guideline-recommended classification system. 
 
Conclusion 
In summary, AF is a progressive disease in most patients with a significant annual progression 
rate identified in two AF all-comer cohorts. Clinical predictors of progression have also been 
identified. Future studies need to demonstrate whether the progression rate can be reduced by 
targeting modifiable predictors. More importantly, it needs to be shown whether AF progression 
is associated with adverse events, and whether prevention of progression improves outcomes in 
AF and needs to be integrated into AF management.  
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FIGURE LEGENDS 
 
Figure 1. The number and proportion of atrial fibrillation types at baseline and at one year 
follow-up are provided in A) the total PRFER in AF Prolongation study (N=3063) and B) patients 
with atrial fibrillation diagnosed <1 year (N=1063). Slightly lower numbers compared to the 
baseline table are due to missing information of atrial fibrillation type at follow-up. 
 
Figure 2. Logistic stepwise selection model for predictors of atrial fibrillation progression in the 
PREFER in AF Prolongation study. Odds ratios and 95% confidence intervals are provided per 
standard deviation (duration of atrial fibrillation) or presence of the condition. The continuous 
variable atrial fibrillation duration entered analyses logarithmically transformed log(1+atrial 
fibrillation duration in years). Cardioversion indicates cardioversion in the last 12 months. 
Analyses were performed in the subgroup of patients with all variables available (N=2495). 
 
